Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis - PubMed (original) (raw)

Randomized Controlled Trial

Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis

Opeolu Adeoye et al. Stroke. 2015 Feb.

Abstract

Background and purpose: The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial demonstrated safety of recombinant tissue-type plasminogen activator (r-tPA) plus eptifibatide in acute ischemic stroke (AIS). CLEAR-ER randomized AIS patients (5:1) to 0.6 mg/kg r-tPA plus eptifibatide versus standard r-tPA (0.9 mg/kg). Interventional Management of Stroke III randomized AIS patients to r-tPA plus endovascular therapy versus standard r-tPA. Albumin in Acute Stroke Part 2 randomized patients to albumin±r-tPA versus saline±r-tPA. Our aim was to compare outcomes in CLEAR-ER combination arm patients to propensity score-matched r-tPA only subjects in Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III.

Methods: The primary outcome was 90-day severity-adjusted modified Rankin score (mRS) dichotomization based on baseline National Institutes of Health Stroke Scale. Secondary outcomes were 90-day mRS dichotomization as excellent (mRS, 0-1); mRS dichotomization as favorable (mRS, 0-2); and nonparametric analysis of the ordinal mRS.

Results: Eighty-five combination arm CLEAR-ER subjects were matched with 169 Albumin in Acute Stroke Part 2 and Interventional Management of Stroke III trials' r-tPA only patients (controls). Median age in CLEAR-ER and control subjects was 68years; median National Institutes of Health Stroke Scale in the CLEAR-ER subjects was 11 and in control subjects 12. At 90 days, CLEAR-ER subjects had a nonsignificantly greater proportion of patients with favorable outcomes (45% versus 36%; unadjusted relative risks, 1.24; 95% confidence intervals, 0.91-1.69; P=0.18). Secondary outcomes were 52% versus 34% excellent outcomes (relative risks, 1.51; 95% confidence intervals, 1.13-2.02; P=0.007); 60% versus 53% favorable outcome (relative risks, 1.13; 95% confidence intervals, 0.90-1.41; P=0.31); and ordinal Cochran-Mantel-Haenszel P=0.10.

Conclusion: r-tPA plus eptifibatide showed a favorable direction of effect that was consistent across multiple approaches for AIS outcome evaluation. A phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes is warranted.

Keywords: clinical trial; eptifibatide; tissue-type plasminogen activator.

PubMed Disclaimer

Figures

Figure

mRS Distributions

Cited by

European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.
Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, de la Ossa NP, Strbian D, Tsivgoulis G, Turc G. Berge E, et al. Eur Stroke J. 2021 Mar;6(1):I-LXII. doi: 10.1177/2396987321989865. Epub 2021 Feb 19. Eur Stroke J. 2021. PMID: 33817340 Free PMC article.
Repeated Intravenous Thrombolysis in Patients with Recurrent Ischemic Stroke in the Vertebrobasilar Territory.
Černík D, Ospalík D, Šaňák D, Cihlář F. Černík D, et al. Case Rep Neurol. 2021 Jul 29;13(2):510-514. doi: 10.1159/000518193. eCollection 2021 May-Aug. Case Rep Neurol. 2021. PMID: 34720955 Free PMC article.
Interpretation of Brain CT Scans in the Field by Critical Care Physicians in a Mobile Stroke Unit.
Hov MR, Zakariassen E, Lindner T, Nome T, Bache KG, Røislien J, Gleditsch J, Solyga V, Russell D, Lund CG; NASPP study group. Hov MR, et al. J Neuroimaging. 2018 Jan;28(1):106-111. doi: 10.1111/jon.12458. Epub 2017 Jul 27. J Neuroimaging. 2018. PMID: 28766306 Free PMC article.
Acute Treatment of Stroke (Except Thrombectomy).
Venturelli PM, Appleton JP, Anderson CS, Bath PM. Venturelli PM, et al. Curr Neurol Neurosci Rep. 2018 Sep 18;18(11):77. doi: 10.1007/s11910-018-0883-x. Curr Neurol Neurosci Rep. 2018. PMID: 30229395 Review.
Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion/stenosis of anterior circulation (SE-GRACE): study protocol for a randomized controlled trial.
Huang K, Ji Z, Wu Y, Huang Y, Li G, Zhou S, Yang Z, Huang W, Yang G, Weng G, Chen P, Pan S. Huang K, et al. BMC Neurol. 2020 Jun 11;20(1):239. doi: 10.1186/s12883-020-01823-z. BMC Neurol. 2020. PMID: 32527232 Free PMC article.

References

1. The national institute of neurological disorders and stroke rt-pa stroke study group. Tissue plasminogen activator for acute ischemic stroke. The New England journal of medicine. 1995;333:1581–1587. - PubMed
1. Pancioli AM, Adeoye O, Schmit PA, Khoury J, Levine SR, Tomsick TA, et al. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke; a journal of cerebral circulation. 2013;44:2381–2387. - PMC - PubMed
1. Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Ovbiagele B, et al. Collateral flow predicts response to endovascular therapy for acute ischemic stroke. Stroke; a journal of cerebral circulation. 2011;42:693–699. - PMC - PubMed
1. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, et al. High-dose albumin treatment for acute ischaemic stroke (alias) part 2: A randomised, double-blind, phase 3, placebo-controlled trial. The Lancet. Neurology. 2013;12:1049–1058. - PMC - PubMed
1. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke; a journal of cerebral circulation. 2012;43:1171–1178. - PubMed

Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis - PubMed (original) (raw)